Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Open-Label Study of MOR00208 in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
2012-002659-41Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in non-Hodgkin lymphoma (NHL), sponsored by MorphoSys AG. Primary endpoint: Overall response rate. Started Oct 2012; status: completed.
02
Drugs
tafasitamab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2012-002659-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002659-41.